Empowered Funds LLC Buys 113,929 Shares of Sarepta Therapeutics, Inc. $SRPT

Empowered Funds LLC raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,898,816.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 113,935 shares of the biotechnology company’s stock after buying an additional 113,929 shares during the quarter. Empowered Funds LLC’s holdings in Sarepta Therapeutics were worth $2,479,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Yousif Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 1.9% during the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after acquiring an additional 481 shares during the period. PNC Financial Services Group Inc. lifted its position in Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 636 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sarepta Therapeutics by 1.8% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares during the period. Finally, Larson Financial Group LLC boosted its stake in Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 851 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $15.93 on Thursday. Sarepta Therapeutics, Inc. has a 12 month low of $14.68 and a 12 month high of $25.32. The company’s fifty day simple moving average is $16.95 and its 200-day simple moving average is $18.55. The firm has a market cap of $1.68 billion, a PE ratio of -16.59, a P/E/G ratio of 0.18 and a beta of 0.23. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. During the same quarter last year, the firm earned $2.02 earnings per share. The firm’s revenue for the quarter was down 34.3% compared to the same quarter last year. Equities research analysts expect that Sarepta Therapeutics, Inc. will post 3.89 EPS for the current fiscal year.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Sarepta reported second-quarter 2026 adjusted earnings of $0.64 per share, exceeding estimates ranging from $0.22 to $0.58. Revenue of $401.25 million also surpassed the $366.39 million consensus estimate, producing earnings and revenue surprises of approximately 10.35% and 12.85%, respectively. Sarepta Therapeutics Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company highlighted approximately $328.7 million in product revenue and said its rare-disease medicines continue to support its commercial foundation. New CEO Michael Severino also pointed to potential opportunities ahead as he begins his tenure. Sarepta Announces Second-Quarter Results and Corporate Developments
• Neutral Sentiment: The earnings release included recent corporate developments, but the available reports did not identify a major new guidance change or specific catalyst likely to materially alter near-term forecasts. Sarepta Therapeutics Announces Second-Quarter 2026 Financial Results
• Negative Sentiment: Despite beating estimates, revenue fell 34.3% year over year from $2.02 per share in the prior-year quarter, while the latest earnings result was substantially below the year-ago level. The weaker underlying trend likely outweighed the quarterly beat for investors. Sarepta Therapeutics Quarterly Earnings Results

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, July 9th. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Finally, Piper Sandler dropped their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $24.72.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.